Skip to main content
. 2016 Jun;6(2):168–173. doi: 10.1086/685715

Figure 2.

Figure 2

Flow-mediated vasodilation (FMD, mean + SEM) before (baseline; gold bars) and after (blue bars) 3 months of bosentan treatment in patients with idiopathic pulmonary arterial hypertension (IPAH) or PAH with other comorbidities (left) or patients who had PAH with collagen tissue disease (CTD; right).